• MK-571 (L-660,711): Mechanistic Leverage in Immune Cell Prot

  2026-07-16

  An in-depth exploration of how MK-571 (L-660,711) enables translational researchers to dissect leukotriene-mediated inflammation and multidrug resistance mechanisms in immune cells. Integrating recent mechanistic discoveries, this article provides strategic guidance for leveraging MK-571 in advanced inflammation and drug resistance studies, bridging bench findings to translational relevance.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): App

  2026-07-16

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a precision anion transport inhibitor enabling targeted modulation of chloride channel function in cancer, neuroprotection, and vascular research. This article delivers actionable protocol guidance, workflow optimization, and troubleshooting strategies—bridging cutting-edge metastasis research with real-world assay design.

• Fludarabine in Neoantigen-Driven Immuno-Oncology: Mechanisti

  2026-07-15

  Explore how Fludarabine, a potent DNA synthesis inhibitor, is redefining immuno-oncology by enhancing neoantigen presentation and T cell therapy efficacy. This article delivers technical insights and practical guidance to advance leukemia and multiple myeloma research.

• Human iPSC-Derived Sensory Neurons Model HSV-1 Latency and R

  2026-07-15

  This study establishes a robust, scalable protocol to generate excitable human sensory neurons from inducible pluripotent stem cells (hiPSCs), enabling direct modeling of herpes simplex virus 1 (HSV-1) latency and reactivation in a human system. The platform overcomes critical translational barriers by replicating hallmark features of HSV-1 latency, providing a powerful research tool for investigating viral persistence and potential therapeutic strategies.

• Uridine, Trisodium Salt: Transforming RNA Biosynthesis Workf

  2026-07-14

  Uridine, Trisodium Salt from APExBIO empowers researchers to achieve unprecedented precision and efficiency in RNA-mediated genome engineering. This article bridges the latest PRINT technology and high-purity nucleoside analog use, offering actionable workflows and troubleshooting strategies for reproducible transgene insertion and vascular research.

• Sulfo-NHS-LC-Biotin: Practical Guide for Surface Protein Bio

  2026-07-14

  Sulfo-NHS-LC-Biotin enables selective, irreversible biotin labeling of primary amines on cell surface proteins, supporting workflows that require stable, extracellular modification. It is not suitable for intracellular, reversible, or non-protein biotinylation applications, and its membrane-impermeable nature should be matched to experimental goals.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guidance and Best

  2026-07-13

  Cy3 NHS ester (non-sulfonated) enables precise fluorescent labeling of proteins, peptides, and oligonucleotides by targeting primary amino groups. It is optimal for workflows that tolerate organic co-solvents and require bright orange emission for imaging or quantification. This reagent should not be used in aqueous-only protocols or where long-term storage of dye solutions is required.

• DIDS: Mechanistic Insights and Translational Leverage in Ion

  2026-07-13

  Explore the multifaceted role of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) in chloride channel research and tumor biology. This article delivers a mechanistic perspective on DIDS, highlighting its impact on experimental strategy and its translational promise.

• DFCP1 Regulates Starvation-Induced ATGL Lipolysis in Lipid D

  2026-07-12

  This study identifies DFCP1 as a nutrient-sensitive modulator of lipid droplet (LD) catabolism, specifically by controlling the localization and activity of ATGL during starvation. The findings clarify how DFCP1 restricts ATGL-mediated lipolysis, offering new mechanistic insight into cellular lipid homeostasis and providing a foundation for experimental protocols targeting metabolic stress.

• VX-702: Selective p38α MAPK Inhibitor for Inflammation Model

  2026-07-10

  VX-702 is a potent, selective p38α MAPK inhibitor that blocks kinase activity and suppresses pro-inflammatory cytokines such as IL-6, IL-1β, and TNFα. Its dual-action mechanism includes both ATP-competitive inhibition and promotion of kinase dephosphorylation, making it valuable for inflammation and arthritis research.

• Histone H4K12 Lactylation Drives TNBC Progression via SLFN5

  2026-07-09

  This study uncovers a novel epigenetic mechanism in triple-negative breast cancer (TNBC), demonstrating that histone H4K12 lactylation, induced by tumor-derived lactate, promotes malignancy by downregulating Schlafen 5 (SLFN5). The findings reveal that targeting lactate-driven histone modifications—such as with sodium oxamate—can disrupt this pathway, highlighting new strategies for cancer metabolism research.

• DIDS: Mechanistic Insights and Translational Impact in Chann

  2026-07-09

  Explore the advanced mechanisms and translational research value of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid), with a scientific deep-dive into its chloride channel inhibition and unique experimental applications. This comprehensive guide highlights recent breakthroughs and practical protocol strategies for biomedical investigators.

• CX-4945 (Silmitasertib): Dissecting CK2 Inhibition in Cancer

  2026-07-08

  Explore how CX-4945 (Silmitasertib) empowers advanced cancer research through selective CK2 inhibition, with a focus on stemness and chemoresistance in lung cancer. This article uniquely unpacks mechanistic insights and experimental protocols for translational oncology.

• Cholesterol Sensing by Frizzled5 Links Lipid Metabolism and

  2026-07-08

  The reference study uncovers a novel mechanism in which Frizzled5 (Fzd5) uniquely binds cholesterol via its extracellular linker, enabling receptor palmitoylation and plasma membrane trafficking. This finding reveals how aberrant cholesterol metabolism directly fuels Wnt/β-catenin signaling and tumor growth in pancreatic ductal adenocarcinoma, highlighting Fzd5 as a pivotal molecular bridge and potential therapeutic target.

• (5Z)-7-Oxozeaenol: Selective TAK1 Inhibitor for Inflammation

  2026-07-07

  (5Z)-7-Oxozeaenol is a nanomolar-potency, highly selective TAK1 inhibitor that disrupts pro-inflammatory signaling pathways such as NF-κB and JNK/p38 MAPK. Its irreversible inhibition profile and robust in vitro and in vivo activity make it a benchmark compound for dissecting TAK1-mediated processes in inflammation and cancer models.

15653 records 1/1044 page Next 12345 下5页 Last page